HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

2 years ago

Southlake, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the…

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

2 years ago

Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third…

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

2 years ago

Vaxxinity corporate headquarters in Cape Canaveral, Fla. Vaxxinity corporate headquarters in Cape Canaveral, Fla. (Photo: Vaxxinity)CAPE CANAVERAL, Fla., May 09,…

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

2 years ago

Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical…

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

2 years ago

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated…

Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results

2 years ago

Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom…

ORYZON to Give Updates on Corporate Progress in May-June

2 years ago

BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023MADRID and…

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

2 years ago

Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss…

Immutep to Participate in the JMP Securities Life Sciences Conference

2 years ago

Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),…

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

2 years ago

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and…